OBJECTIVE: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a useful inflammatory marker of cardiovascular risk, yet little is known of its prognostic role in heart failure (HF). We evaluated the association of Lp-PLA2 with mortality in subjects with HF and assessed its incremental value for risk discrimination over established risk factors and biomarkers. METHODS: Residents of Olmsted County, MN, diagnosed with HF between September 2003 and April 2007 (n=646, mean age 76 years, 51% women) were prospectively enrolled and followed-up. Plasma Lp-PLA2 levels were measured at baseline and evaluated along with known risk indicators. RESULTS: Lp-PLA2 was positively associated with male gender and low-density lipoprotein cholesterol and inversely associated with statin use and diabetes. During follow-up (median 21 months), 213 deaths occurred. Elevated Lp-PLA2 was associated with an increased risk of mortality (hazard ratio (HR)=1.57; 95% confidence interval (CI): 1.03-2.37; P=0.035, per 1-unit increase in the log-transformed values). The relationship differed markedly by age (P(interaction)=0.003), with a strong association in patients under 80 years (covariate-adjusted HR=3.83; 95% CI: 1.93-7.61; P<0.001) and none in older ones (covariate-adjusted HR=0.82; 95% CI: 0.44-1.51; P=0.55). For the younger subjects, an improvement in the model's discriminatory power was obtained by adding Lp-PLA2 to established risk indicators and biomarkers (area under the receiver operating characteristic curve, 0.709-0.744, P(difference)=0.008). CONCLUSION: In this community-based cohort of patients with HF, Lp-PLA2 was strongly and independently associated with mortality and contributed incrementally to risk discrimination in patients under 80 years of age.
OBJECTIVE:Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a useful inflammatory marker of cardiovascular risk, yet little is known of its prognostic role in heart failure (HF). We evaluated the association of Lp-PLA2 with mortality in subjects with HF and assessed its incremental value for risk discrimination over established risk factors and biomarkers. METHODS: Residents of Olmsted County, MN, diagnosed with HF between September 2003 and April 2007 (n=646, mean age 76 years, 51% women) were prospectively enrolled and followed-up. Plasma Lp-PLA2 levels were measured at baseline and evaluated along with known risk indicators. RESULTS:Lp-PLA2 was positively associated with male gender and low-density lipoprotein cholesterol and inversely associated with statin use and diabetes. During follow-up (median 21 months), 213 deaths occurred. Elevated Lp-PLA2 was associated with an increased risk of mortality (hazard ratio (HR)=1.57; 95% confidence interval (CI): 1.03-2.37; P=0.035, per 1-unit increase in the log-transformed values). The relationship differed markedly by age (P(interaction)=0.003), with a strong association in patients under 80 years (covariate-adjusted HR=3.83; 95% CI: 1.93-7.61; P<0.001) and none in older ones (covariate-adjusted HR=0.82; 95% CI: 0.44-1.51; P=0.55). For the younger subjects, an improvement in the model's discriminatory power was obtained by adding Lp-PLA2 to established risk indicators and biomarkers (area under the receiver operating characteristic curve, 0.709-0.744, P(difference)=0.008). CONCLUSION: In this community-based cohort of patients with HF, Lp-PLA2 was strongly and independently associated with mortality and contributed incrementally to risk discrimination in patients under 80 years of age.
Authors: Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor Journal: Circulation Date: 2003-01-28 Impact factor: 29.690
Authors: T Häkkinen; J S Luoma; M O Hiltunen; C H Macphee; K J Milliner; L Patel; S Q Rice; D G Tew; K Karkola; S Ylä-Herttuala Journal: Arterioscler Thromb Vasc Biol Date: 1999-12 Impact factor: 8.311
Authors: K L Carpenter; I F Dennis; I R Challis; D P Osborn; C H Macphee; D S Leake; M J Arends; M J Mitchinson Journal: FEBS Lett Date: 2001-09-21 Impact factor: 4.124
Authors: C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe Journal: N Engl J Med Date: 2000-10-19 Impact factor: 91.245
Authors: Sarah Lewington; Gary Whitlock; Robert Clarke; Paul Sherliker; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Richard Peto; Rory Collins Journal: Lancet Date: 2007-12-01 Impact factor: 79.321
Authors: Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino Journal: Circulation Date: 2003-03-25 Impact factor: 29.690
Authors: Josie A Blackie; Jackie C Bloomer; Murray J B Brown; Hung Yuan Cheng; Beverley Hammond; Deirdre M B Hickey; Robert J Ife; Colin A Leach; V Ann Lewis; Colin H Macphee; Kevin J Milliner; Kitty E Moores; Ivan L Pinto; Stephen A Smith; Ian G Stansfield; Steven J Stanway; Maxine A Taylor; Colin J Theobald Journal: Bioorg Med Chem Lett Date: 2003-03-24 Impact factor: 2.940
Authors: Sheila M Manemann; Jennifer L St Sauver; Hongfang Liu; Nicholas B Larson; Sungrim Moon; Paul Y Takahashi; Janet E Olson; Walter A Rocca; Virginia M Miller; Terry M Therneau; Che G Ngufor; Veronique L Roger; Yiqing Zhao; Paul A Decker; Jill M Killian; Suzette J Bielinski Journal: BMJ Open Date: 2021-06-08 Impact factor: 3.006